Zobrazeno 1 - 10
of 12 471
pro vyhledávání: '"Lipid lowering"'
Autor:
Xin Hu, Xiaoming Wang
Publikováno v:
Guoji laonian yixue zazhi, Vol 45, Iss 5, Pp 601-605 (2024)
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular diseases. Recent advancements in lipid-lowering therapies have seen progress with statins, cholesterol absorption inhibitors, PCSK9 inhibitors, and omega-3 fatty acids becoming wi
Externí odkaz:
https://doaj.org/article/28dad1aec4434deea592105c77462544
Publikováno v:
Applied Biological Chemistry, Vol 67, Iss 1, Pp 1-12 (2024)
Abstract Probiotics have been shown to provide health benefits for several metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD), by modulating the gut microbiota. In this study,
Externí odkaz:
https://doaj.org/article/bb86688157c8449c95081a0d0e17edd9
Publikováno v:
Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-7 (2024)
Abstract Background Lipid-lowering therapy (LLT) plays a central role in managing atherosclerotic cardiovascular disease (ASCVD) risk, but its underuse is reported in over 40% of the qualified population in the United States. Studies on factors, part
Externí odkaz:
https://doaj.org/article/c263d92166d14e80a1679aec2147ff78
Preparation, Amino Acid Composition and Activity of Tartary Buckwheat Protein Lipid-lowering Peptide
Publikováno v:
Shipin gongye ke-ji, Vol 45, Iss 21, Pp 129-139 (2024)
Tartary buckwheat was used as raw material to extract tartary buckwheat protein, and the enzymatic hydrolysis conditions of tartary buckwheat protein lipid-lowering peptides were screened by single factor and response surface optimization experiments
Externí odkaz:
https://doaj.org/article/effe5dfa293647e4a5cb1bcb7321fc28
Publikováno v:
Zhongguo youzhi, Vol 49, Iss 10, Pp 56-61 (2024)
旨在为动物源性与植物源性脂质复配保健品的研发提供参考，以高脂饮食诱导建立SD大鼠混合型高脂血症动物模型，揭示蛋黄磷脂与紫苏籽油复配对维持大鼠血脂健康水平的影响。将50只雄性
Externí odkaz:
https://doaj.org/article/a9e430b14f5d47f484ef4425a7f68533
Autor:
S. S. Vedenskaya, O. G. Smolenskaya
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 4, Pp 426-432 (2024)
Aim. To establish the frequency of achieving target of blood pressure (BP) levels and lipid spectrum parameters (LS) in patients with arterial hypertension (AH) and multifocal atherosclerotic lesion (MFAL) with normal and elevated levels of lipoprote
Externí odkaz:
https://doaj.org/article/3b1121541acf42a5bb07fb39fb5a5461
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract To determine the potential causal association between serum lipid levels and sarcoidosis, and to investigate the potential impact of lipid lowering agents on sarcoidosis. Two-sample Mendelian randomization (TSMR) was used to investigate the
Externí odkaz:
https://doaj.org/article/85a07ef2551142079ec706bb76d77bbd
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-12 (2024)
Abstract Background We assessed long-term real-world effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). Methods Retrospective case series of six patients with HoFH treated with lomitapide in an It
Externí odkaz:
https://doaj.org/article/b64fe9e26f4e463ea73a2ef50710ac2c
Publikováno v:
Shipin gongye ke-ji, Vol 45, Iss 20, Pp 87-97 (2024)
To address the issues of low bioavailability, degradation during processing, and limited use in precision nutrition of anthocyanins (ACNs). ACNs nanoparticles using ACNs as the core, soybean lecithin constructed-Liposome (Lipo), and Gum Arabic (GA) a
Externí odkaz:
https://doaj.org/article/b249f3476a384853ac108b70fe43eba1
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background The pathogenesis of type 2 diabetes mellitus is somewhat associated with lipid metabolism. We aim to assess the impact of lipid-lowering drugs (HMGCR inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors) on type 2 diabetes mellitus
Externí odkaz:
https://doaj.org/article/89524b073f34488abd93417b31f606f5